Tamarind Bio
Tamarind Bio offers protein engineering tools including AlphaFold, RFdiffusion, MPNN, and GROMACS and requires no deployment.
- 2
- San Francisco, CA, USUnited States
Tamarind Bio offers protein engineering tools including AlphaFold, RFdiffusion, MPNN, and GROMACS and requires no deployment.
tamarind.bioCrawled Oct 14, 2026
The page features articles on computational protein design and AI in life sciences, including model comparisons, de novo therapeutics, research protocols, and benchmarking.
Tamarind Bio offers Free, Premium, and Enterprise plans with options for API access, custom models, and job capacity.
Tamarind Bio handles product and support inquiries through calls with its founders and email for general inquiries.
Tamarind Bio offers computational biology tools to design and score proteins, peptides, and small molecules, including AlphaFold, RFdiffusion, BoltzGen, GROMACS, and more than 250 other models.
GenScript and Tamarind Bio are collaborating to integrate Tamarind Bio’s AI-driven molecular design platform with GenScript’s wet-lab expertise. The partnership aims to accelerate drug discovery by bridging digital AI-generated molecular models with hands-on lab validation. Researchers can now streamline the transition from computational design to experimental testing.
Aug 2026PR NewswireNews article
Tamarind Bio builds AI infrastructure for biotech research and development. Eli Lilly’s TuneLab program has chosen Tamarind Bio as a third-party technology partner to develop, host, and operate the inference infrastructure layer for TuneLab2.0, which is now operational.
Jun 2026Menlo TimesNews article
Tamarind Bio launches AI-powered molecular models for drug discovery, eliminating the need for machine learning expertise. The company secures $13.6M in funding, with Dimension Capital leading a $12M Series A round. Founders Deniz Kavi and Sherry Liu aim to streamline drug research for scientists.
Feb 2026Menlo TimesNews article
Tamarind Bio secures $13.6 million in Series A funding to scale its no-code platform, which integrates over 200 AI and simulation models for life-science researchers. The platform is already adopted by around 100 biotech firms, including eight of the top 20 pharmaceutical companies such as Bayer and Boehringer Ingelheim. Dimension Capital leads the round, with participation from Y Combinator.
Feb 2026biopharmatrend.comNews article
